"Critical Path" Priorities List Likely To Include Clinical Trial Design, FDAer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA expects to release its Critical Path opportunities list by the end of the summer. Issues concerning clinical trial design and biomarkers appeared "orders of magnitude" more often than other topics in stakeholder comments, FDA Regulatory Counsel Rovin says at BIO annual meeting.
You may also be interested in...
Critical Path Opportunities List Previewed By FDA
FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.
Critical Path Opportunities List Previewed By FDA
FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.
FDA "Critical Path" Faces Roadblock
The agency plans to release its list of top priorities several months behind schedule while it focuses on drug safety issues, Acting Deputy Commissioner Woodcock says. Limited FDA resources may jeopardize the project as well.